DNA X, Inc. received notification from the Nasdaq Hearings Panel that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders' equity of at least $2.5 million. Although compliance was restored as of July 24, 2026, securities remain subject to delisting if rules are violated until November 18, 2026. The company is now under mandatory panel monitoring until August 28, 2027; failure to maintain equity compliance during this period will trigger an automatic delisting determination without a cure period. DNA X, Inc. operates in the biotechnology industry and develops automated systems for high-throughput DNA sequencing.

DNA X, Inc. filed an amendment to update disclosure regarding the sale of remaining Series B Preferred Stock shares under a Purchase Agreement on August 7, 2026. The company issued 416,667 shares in exchange for $2.5 million in cash proceeds. Management states that this transaction brings stockholders' equity above the $2.5 million minimum requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1). The filing includes a pro forma summary of stockholders' equity, projecting an ending balance of $5,840 thousand as of August 7, 2026. The company is awaiting formal determination from Nasdaq regarding compliance with the Equity Rule and intends to provide an update upon receipt. DNA X, Inc. operates in the biotechnology industry, specializing in genomic sequencing technologies.

DNA X, Inc. issued 929,864 shares of Series B Preferred Stock on July 8, 2026, generating $2.5 million in cash proceeds and facilitating the cancellation of a $3.1 million convertible promissory note balance. The company expects to issue the remaining 416,667 shares under the Purchase Agreement by August 14, 2026. Following these transactions, the company's pro forma stockholders' equity is estimated at $3.798 million, which exceeds the $2.5 million minimum requirement for continued listing on the Nasdaq Capital Market. DNA X, Inc. is a technology company.

DNA X, Inc. entered into a securities purchase agreement with DNA Holdings Venture, Inc. on June 29, 2026, to issue 1,346,531 shares of non-voting Series B Convertible Preferred Stock at $6.00 per share for an aggregate price of $8.1 million. The transaction includes $5.0 million in cash and the cancellation of a $3.1 million convertible promissory note. DNA X, Inc. operates in the technology sector and develops the DNA-X platform.